Kbc Group Nv Adverum Biotechnologies, Inc. Transaction History

Kbc Group Nv

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$2.08 - $3.6 $4,368 - $7,560	-2,100 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$9.26 - $14.36 $18,520 - $28,720	2,000 Added 2000.0%	2,100 $21,000
Q4 2019 Feb 11, 2020	SELL	$5.12 - $12.22 $537 - $1,283	-105 Reduced 51.22%	100 $1,000
Q3 2019 Nov 07, 2019	SELL	$5.24 - $15.89 $10,453 - $31,700	-1,995 Reduced 90.68%	205 $1,000
Q2 2019 Dec 03, 2019	BUY	$5.1 - $11.89 $11,220 - $26,158	2,200 New	2,200 $26,000
Q2 2019 Jul 30, 2019	SELL	$5.1 - $11.89 $11,220 - $26,158	-2,200 Closed	0 $0
Q1 2019 Dec 03, 2019	BUY	$3.03 - $6.02 $6,666 - $13,243	2,200 New	2,200 $12,000
Q1 2019 May 10, 2019	SELL	$3.03 - $6.02 $6,666 - $13,243	-2,200 Closed	0 $0
Q4 2018 Dec 03, 2019	BUY	$2.87 - $5.92 $6,314 - $13,024	2,200 New	2,200 $7,000
Q4 2018 Jan 31, 2019	SELL	$2.87 - $5.92 $6,314 - $13,024	-2,200 Closed	0 $0
Q3 2018 Dec 03, 2019	BUY	$4.5 - $7.6 $9,900 - $16,720	2,200 New	2,200 $13,000
Q3 2018 Nov 14, 2018	SELL	$4.5 - $7.6 $9,900 - $16,720	-2,200 Closed	0 $0
Q2 2018 Dec 03, 2019	BUY	$5.3 - $6.9 $11,660 - $15,180	2,200 New	2,200 $12,000
Q2 2018 Aug 03, 2018	SELL	$5.3 - $6.9 $11,660 - $15,180	-2,200 Closed	0 $0
Q1 2018 Dec 03, 2019	BUY	$3.65 - $7.95 $8,030 - $17,490	2,200 New	2,200 $13,000

2.53M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $697M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.